CPRX


Roth Capital Weighs in on Catalyst Pharmaceuticals Inc (CPRX) Following Meeting with Management

Roth Capital analyst Scott Henry is out today with a research note on shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), following recent meeting with the company’s senior management. …

Company Update (NASDAQ:CPRX): Here’s Why Catalyst Pharmaceuticals Inc Shares Are Up 25% Today

Investors in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) are having a great day. Shares of the biotech are up nearly 25% in the wake of analyst upgrade.

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the …

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Launch of Expanded Access Program Website and Participation at the American Association of Neuromuscular & Electrodiagnostic Medicine Conference

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced the launch of a new website for its expanded access program (EAP) and its planned participation at the 63rd …

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Second Quarter 2016 Financial Results and Provides Product Development Update

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results …

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it …

Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc’s Firdapse Phase 3 Study Published in Muscle & Nerve

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported on the …

Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Reduction in Workforce as Part of Operating Expense Management Plan

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the …

Zacks’ Insights: Apple Inc. (AAPL), Gilead Sciences, Inc. (GILD), Catalyst Pharmaceuticals Inc (CPRX),

Apple Inc. After the bell Tuesday, tech bellwether Apple Inc.

Tuesday Morning’s Market Insights: Sarepta Therapeutics Inc (SRPT), NXP Semiconductors NV (NXPI), Exelixis, Inc. (EXEL), Catalyst Pharmaceuticals Inc (CPRX)

Sarepta Therapeutics Inc (NASDAQ:SRPT) is down over 45% in pre-market trading following a negative vote by an FDA advisory panel regarding the effectiveness …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts